Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion
September 2, 2015 4:30 PM EDTPHILADELPHIA, Pa., Sept. 2, 2015 /PRNewswire/ --
Transaction Highlights:
Substantially increases, diversifies revenue base with highly profitable specialty products Expands pipeline with exciting products Near-term growth potential with 11 product applications pending at the FDA, of which five include Paragraph IV certifications Provides medium and longer term growth potential with 17 product candidates in development, including eight controlled substances Adds development expertise in difficult to formulate generics, including various dosage forms Accretive to adjusted EPS in fiscal 2016 in the... More